Last updated: 07/17/2024 16:52:32

A study comparing the efficacy, safety and tolerability of fixed dose combination (FDC) of FF/UMEC/VI with the FDC of FF/VI and UMEC/VI; administered once-daily via a dry powder inhaler (DPI) in subjects with chronic obstructive pulmonary disease (COPD)

Request patient level data
GSK study ID
116855
See study documents
Clinicaltrials.gov ID
NCT02164513
See results summary
EudraCT ID
2013-003075-35
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual combinations of FF/VI and UMEC/VI, all administered once-daily in the morning via a dry powder inhaler in subjects with chronic obstructive pulmonary disease
Trial description: The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an ‘open’ triple therapy (use of Inhaled Corticosteroid [ICS]/ Long-acting Muscarinic Receptor Antagonists [LAMA])/ Long Acting Beta-Agonist [LABA] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Annual rate of on-treatment moderate/severe exacerbations comparing FF/UMEC/VI with UMEC/VI and FF/VI

Timeframe: Up to Week 52

Secondary outcomes:

Change from Baseline in trough Forced expiratory volume in 1 second (FEV1), at Week 52 comparing FF/UMEC/VI with FF/VI

Timeframe: Baseline and Week 52

Change from Baseline in St. George’s Respiratory Questionnaire for (SGRQ) Total Score at Week 52 comparing FF/UMEC/VI with FF/VI

Timeframe: Baseline and Week 52

Time to first on-treatment moderate/severe exacerbation comparing FF/UMEC/VI with FF/VI and with UMEC/VI

Timeframe: Up to Week 52

Annual rate of on-treatment moderate/severe exacerbations comparing FF/UMEC/VI with UMEC/VI in the subset of participants with a blood eosinophil count >=150 cells per microliter

Timeframe: Up to Week 52

Time to first on-treatment moderate/severe exacerbation comparing FF/UMEC/VI with UMEC/VI in the subset of particpants with a blood eosinophil count >=150 cells per microliter at Baseline

Timeframe: Up to Week 52

Annual rate of on-treatment severe exacerbations comparing FF/UMEC/VI with FF/VI and with UMEC/VI

Timeframe: Up to Week 52

Interventions:
Drug: fluticasone furoate (FF)
Drug: vilanterol (VI)
Drug: umeclidinium bromide (UMEC)
Enrollment:
10355
Observational study model:
Not applicable
Primary completion date:
2017-17-07
Time perspective:
Not applicable
Clinical publications:
David A. Lipson, Frank Barnhart, Noushin Brealey, Jean Brooks, Gerard Criner, Nicola Day, Mark Dransfield, David Halpin, Meilan Han, C Elaine Jones, Sally Kilbride, Peter Lange, David Lomas, Fernando J. Martinez, David Singh, Maggie Tabberer, Bob Wise, Steven J. Pascoe. Once-Daily Single Inhaler Triple Versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671-1680. DOI: 10.1056/NEJMoa1713901 PMID: 29668352
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
fluticasone furoate, fluticasone furoate/vilanterol, fluticasone furoate/vilanterol/umeclidinium bromide, umeclidinium bromide, umeclidinium bromide/vilanterol, vilanterol
Collaborators
Not applicable
Study date(s)
June 2014 to July 2017
Type
Interventional
Phase
3

Participation criteria

Sex
Female & Male
Age
40+ years
Accepts healthy volunteers
No
  • Informed Consent: A signed and dated written informed consent prior to study participation
  • Type of subject: Outpatient
  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
Inclusion and exclusion criteria
Inclusion criteria:
  • Informed Consent: A signed and dated written informed consent prior to study participation
  • Type of subject: Outpatient
  • Age: Subjects 40 years of age or older at Visit 1
  • Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy OR Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study – screening to safety follow-up contact): Abstinence; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS); Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, “documented” refers to the outcome of the investigator's/designee’s medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject’s medical records. Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
  • COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
  • Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening (visit 1) [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history
  • Severity of COPD symptoms: A score of >=10 on the COPD Assessment Test (CAT) at screening
  • Severity of COPD Disease: A post-albuterol/salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70 at Screening
  • Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only Pro re nata (PRN) COPD medications are not eligible
  • History of Exacerbations: Subjects must demonstrate: a post-bronchodilator FEV1 <50% predicted normal and a documented history of >= 1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator 50% <=FEV1 < 80% predicted normal and a documented history of >= 2 moderate exacerbations or a documented history of >=1 severe COPD exacerbation (hospitalized) in the previous 12 months. Note: Percent predicted will be calculated using the European Respiratory Society Global Lung Function Initiative reference equations. Note: A documented history of a COPD exacerbation (e.g., medical record verification) is a medical record of worsening COPD symptoms that required systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable
  • Liver function tests: alanine aminotransferase (ALT) <2x upper limit of normal (ULN); alkaline phosphatase <=1.5xULN; bilirubin <=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
Exclusion criteria:
  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD)
  • Alpha1-antitrypsin deficiency: Subjects with Alpha1-antitrypsin deficiency as the underlying cause of COPD
  • Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
  • Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening
  • Risk Factors for Pneumonia: immune suppression (e.g. human immunodeficiency virus [HIV], Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson’s Disease, Myasthenia Gravis). Patients at potentially high risk (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator
  • Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded
  • Other Respiratory tract infections that have not resolved at least 7 days prior to screening
  • Abnormal Chest x-ray(CXR): Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or computerised tomography (CT) scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post pneumonia/exacerbation chest x-ray to be over-read by the central vendor or have a chest x-ray conducted at screening. For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz [BfS])
  • Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study
  • Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones).
  • Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets entry criteria
  • Unstable or life threatening cardiac disease: subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure
  • Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Principal Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject’s medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: atrial fibrillation (AF) with rapid ventricular rate >120 beats per minute); sustained or nonsustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate (QTcF) >=500 milliseconds (msec) in patients with QRS <120 msec and QTcF >=530 msec in patients with QRS >=120 msec
  • Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator contraindicates study participation
  • Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment
  • Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liter/minute (L/min) (Oxygen use =<3L/min flow is not exclusionary)
  • Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit
  • Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded
  • Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study
  • Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or study site, or immediate family members of the aforementioned that is involved with this study
  • Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials
  • Medication prior to screening: Use of the following medications within the following time intervals prior to Screening (Visit 1) or during the study: Long term antibiotic therapy Subjects receiving antibiotics for long term therapy are not eligible for the study (Antibiotics are allowed for the short term treatment of an exacerbation or for short term treatment of other acute infections during the study); Systemic, Oral, parenteral corticosteroids 30 days (Except during the study oral/systemic corticosteroids may be used to treat COPD exacerbations/pneumonia) Intra-articular injections are allowed; Any other investigational drug (30 days or 5 half lives whichever is longer)

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
(Badalona) Barcelona, Spain, 08911
Status
Study Complete
Contact us
Location
GSK Investigational Site
(Barakaldo) Vizcaya, Spain, 48903
Status
Study Complete
Contact us
Location
GSK Investigational Site
ALKMAAR, Netherlands, 1815 JD
Status
Study Complete
Contact us
Location
GSK Investigational Site
ALMELO, Netherlands, 7606 SB
Status
Study Complete
Contact us
Location
GSK Investigational Site
ALMELO, Netherlands, 7609 PP
Status
Study Complete
Contact us
Location
GSK Investigational Site
ASSEN, Netherlands, 9401 RK
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aalborg, Denmark, 9100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aarhus C, Denmark, 8000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Abingdon, Virginia, United States, 24210
Status
Study Complete
Contact us
Location
GSK Investigational Site
Adairsville, Georgia, United States, 30103
Status
Study Complete
Contact us
Location
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Afula, Israel, 18101
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aichi, Japan, 455-8530
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aichi, Japan, 457-8511
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aichi, Japan, 460-0001
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aichi, Japan, 471-8513
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aichi, Japan, 485-0041
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aichi, Japan, 489-8642
Status
Study Complete
Contact us
Location
GSK Investigational Site
Albany, New York, United States, 12208
Status
Study Complete
Contact us
Location
GSK Investigational Site
Albuquerque, New Mexico, United States, 87108
Status
Study Complete
Contact us
Location
GSK Investigational Site
Alicante, Spain, 03004
Status
Study Complete
Contact us
Location
GSK Investigational Site
Alzira/Valencia, Spain, 46600
Status
Study Complete
Contact us
Location
GSK Investigational Site
Amanzimtoti, South Africa, 4126
Status
Study Complete
Contact us
Location
GSK Investigational Site
Anderson, South Carolina, United States, 29621
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ankara, Turkey, 06100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ann Arbor, Michigan, United States, 48106
Status
Study Complete
Contact us
Location
GSK Investigational Site
Antwerpen, Belgium, 2060
Status
Study Complete
Contact us
Location
GSK Investigational Site
Arcadia, California, United States, 91007
Status
Study Complete
Contact us
Location
GSK Investigational Site
Aschaffenburg, Bayern, Germany, 63739
Status
Study Complete
Contact us
Location
GSK Investigational Site
Asheville, North Carolina, United States, 28801
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ashkelon, Israel, 78278
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ashville, North Carolina, United States, 28801
Status
Study Complete
Contact us
Location
GSK Investigational Site
Athens, Alabama, United States, 35611
Status
Study Complete
Contact us
Location
GSK Investigational Site
Athens, Georgia, United States, 30606
Status
Study Complete
Contact us
Location
GSK Investigational Site
Auckland, New Zealand, 1051
Status
Study Complete
Contact us
Location
GSK Investigational Site
Auerbach, Sachsen, Germany, 08209
Status
Study Complete
Contact us
Location
GSK Investigational Site
Augsburg, Bayern, Germany, 86150
Status
Study Complete
Contact us
Location
GSK Investigational Site
BEEK, Netherlands, 6191 JW
Status
Study Complete
Contact us
Location
GSK Investigational Site
BELLVILLE, South Africa, 7530
Status
Study Complete
Contact us
Location
GSK Investigational Site
BORÅS, Sweden, SE-506 30
Status
Study Complete
Contact us
Location
GSK Investigational Site
BREDA, Netherlands, 4818 CK
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bad Lippspringe, Nordrhein-Westfalen, Germany, 33175
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bad Woerrishofen, Bayern, Germany, 86825
Status
Study Complete
Contact us
Location
GSK Investigational Site
Badalona, Catalonia, Spain, 08916
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bahía Blanca, Buenos Aires, Argentina, B8000AAK
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bakersfield, California, United States, 93301
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bamberg, Bayern, Germany, 96049
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bangkok, Thailand, 10330
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bangkok, Thailand, 10600
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bangor, Maine, United States, 04401
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08003
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08017
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08023
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08028
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08035
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08036
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barcelona, Spain, 08041
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barnaul, Russia, 656038
Status
Study Complete
Contact us
Location
GSK Investigational Site
Barranquilla, Colombia
Status
Study Complete
Contact us
Location
GSK Investigational Site
Basurto/Bilbao, Spain, 48013
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bay Pines, Florida, United States, 33744
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bayonne cedex, France, 64109
Status
Study Complete
Contact us
Location
GSK Investigational Site
Beijing, China, 100020
Status
Study Complete
Contact us
Location
GSK Investigational Site
Beijing, China, 100029
Status
Study Complete
Contact us
Location
GSK Investigational Site
Beijing, China, 100034
Status
Study Complete
Contact us
Location
GSK Investigational Site
Beijing, China, 100050
Status
Study Complete
Contact us
Location
GSK Investigational Site
Beijing, China, 100191
Status
Study Complete
Contact us
Location
GSK Investigational Site
Belgorod, Russia, 308007
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bellingham, Washington, United States, 98225
Status
Study Complete
Contact us
Location
GSK Investigational Site
Benesov, Czech Republic, 256 30
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berazategui, Argentina, 1884
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berazategui, Buenos Aires, Argentina, B1884AAC
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bergisch Gladbach, Nordrhein-Westfalen, Germany, 51429
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 10119
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 10247
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 10367
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 10625
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 10717
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 10969
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 12043
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 12157
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 12159
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 12203
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 12627
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 13057
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 13086
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 13156
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 13187
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 13581
Status
Study Complete
Contact us
Location
GSK Investigational Site
Berlin, Berlin, Germany, 14059
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bernkastel-Kues, Rheinland-Pfalz, Germany, 54470
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bialystok, Poland, 15-351
Status
Study Complete
Contact us
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35215
Status
Study Complete
Contact us
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35216
Status
Study Complete
Contact us
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35294
Status
Study Complete
Contact us
Location
GSK Investigational Site
Blackpool, Lancashire, United Kingdom, FY3 7EN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Blagoveshchensk, Russia, 675000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bloemfontein, South Africa, 9301
Status
Study Complete
Contact us
Location
GSK Investigational Site
Blumenau, Santa Catarina, Brazil, 89030-101
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bodø, Norway, 8005
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bogota, Colombia
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bogotá, Colombia
Status
Study Complete
Contact us
Location
GSK Investigational Site
Boksburg, Gauteng, South Africa, 1459
Status
Study Complete
Contact us
Location
GSK Investigational Site
Boksburg North, South Africa, 1459
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53119
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53123
Status
Study Complete
Contact us
Location
GSK Investigational Site
Boulder, Colorado, United States, 80301
Status
Study Complete
Contact us
Location
GSK Investigational Site
Boynton Beach, Florida, United States, 33436
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bradford, United Kingdom, BD9 6RJ
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bradford on Avon, Wiltshire, United Kingdom, BA15 1DQ
Status
Study Complete
Contact us
Location
GSK Investigational Site
Braila, Romania, 810003
Status
Study Complete
Contact us
Location
GSK Investigational Site
Brandon, Florida, United States, 33511
Status
Study Complete
Contact us
Location
GSK Investigational Site
Brandys nad Labem, Czech Republic, 250 01
Status
Study Complete
Contact us
Location
GSK Investigational Site
Brasov, Romania, 500283
Status
Study Complete
Contact us
Location
GSK Investigational Site
Brest Cedex, France, 29609
Status
Study Complete
Contact us
Location
GSK Investigational Site
Briis-sous-Forge, France, 91640
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bronx, New York, United States, 10461
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bronx,, New York, United States, 10457
Status
Study Complete
Contact us
Location
GSK Investigational Site
Brugge, Belgium, 8000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Brussels, Belgium, 1200
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bucharest, Romania, 020125
Status
Study Complete
Contact us
Location
GSK Investigational Site
Bucheon city, Gyenggi-do, South Korea, 420-767
Status
Study Complete
Contact us
Location
GSK Investigational Site
Buenos Aires, Argentina, C1425BEN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Buenos Aires, Buenos Aires, Argentina, C1120AAC
Status
Study Complete
Contact us
Location
GSK Investigational Site
Burgos, Spain, 09006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Burlington, Ontario, Canada, L7N 3V2
Status
Study Complete
Contact us
Location
GSK Investigational Site
Butte, Montana, United States, 59701
Status
Study Complete
Contact us
Location
GSK Investigational Site
CABA, Buenos Aires, Argentina
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cairns, Queensland, Australia, 4870
Status
Study Complete
Contact us
Location
GSK Investigational Site
Calabash, North Carolina, United States, 28467
Status
Study Complete
Contact us
Location
GSK Investigational Site
Caloocan City, Philippines, 1400
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cambridge, United Kingdom, CB2 0QQ
Status
Study Complete
Contact us
Location
GSK Investigational Site
Canton, Ohio, United States, 44718
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cape Town, South Africa, 7129
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cape Town, South Africa, 7572
Status
Study Complete
Contact us
Location
GSK Investigational Site
CapeTown, South Africa, 7764
Status
Study Complete
Contact us
Location
GSK Investigational Site
Capital Federal, Argentina, C1440BRR
Status
Study Complete
Contact us
Location
GSK Investigational Site
Carina Heights, Queensland, Australia, 4152
Status
Study Complete
Contact us
Location
GSK Investigational Site
Celebration, Florida, United States, 34747
Status
Study Complete
Contact us
Location
GSK Investigational Site
Centelles (Barcelona), Spain, 08540
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chandler, Arizona, United States, 85284
Status
Study Complete
Contact us
Location
GSK Investigational Site
Changchun, Jilin, China, 130041
Status
Study Complete
Contact us
Location
GSK Investigational Site
Changsha, China, 410013
Status
Study Complete
Contact us
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29406-7108
Status
Study Complete
Contact us
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
Status
Study Complete
Contact us
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28262
Status
Study Complete
Contact us
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28277
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chattanooga, Tennessee, United States, 37404
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chengdu, Sichuan, China, 610041
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cheongju-si, Chungcheongbuk-do, South Korea, 361-763
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chesterfield, Missouri, United States, 63017
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chiangmai, Thailand, 50200
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chiba, Japan, 278-0004
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chiba, Japan, 296-8602
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chicago, Illinois, United States, 60611
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chita, Russia, 672000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chita, Russia, 672090
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chongqing, China
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chongqing, China, 400037
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chongqing, China, 400038
Status
Study Complete
Contact us
Location
GSK Investigational Site
Chula Vista, California, United States, 91910
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45220
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45231
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45245
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ciudad Autonoma de Buenis Aires, Argentina, C1015ABR
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1028AAP
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
Status
Study Complete
Contact us
Location
GSK Investigational Site
Clayton, Victoria, Australia, 3168
Status
Study Complete
Contact us
Location
GSK Investigational Site
Clearwater, Florida, United States, 33759
Status
Study Complete
Contact us
Location
GSK Investigational Site
Clearwater, Florida, United States, 33765-2616
Status
Study Complete
Contact us
Location
GSK Investigational Site
Coeur D'Alene, Idaho, United States, 83814
Status
Study Complete
Contact us
Location
GSK Investigational Site
Colorado Springs, Colorado, United States, 80907
Status
Study Complete
Contact us
Location
GSK Investigational Site
Columbia, Maryland, United States, 21044
Status
Study Complete
Contact us
Location
GSK Investigational Site
Columbia, South Carolina, United States, 29204
Status
Study Complete
Contact us
Location
GSK Investigational Site
Columbus, Georgia, United States, 31904
Status
Study Complete
Contact us
Location
GSK Investigational Site
Columbus, Ohio, United States, 43213
Status
Study Complete
Contact us
Location
GSK Investigational Site
Comuna Alexandru cel Bun, Romania, 617507
Status
Study Complete
Contact us
Location
GSK Investigational Site
Concepcion del Uruguay, Entre Ríos, Argentina, 3260
Status
Study Complete
Contact us
Location
GSK Investigational Site
Concepción, Región Del Biobio, Chile, 4070038
Status
Study Complete
Contact us
Location
GSK Investigational Site
Concord, New South Wales, Australia, 2139
Status
Study Complete
Contact us
Location
GSK Investigational Site
Constanta, Romania, 900002
Status
Study Complete
Contact us
Location
GSK Investigational Site
Conyers, Georgia, United States, 30094
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cordoba, Argentina, 5000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cordoba, Córdova, Argentina, X5003DCE
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cornwall, Ontario, Canada, K6H4M4
Status
Study Complete
Contact us
Location
GSK Investigational Site
Coronel Suarez, Argentina, 7540
Status
Study Complete
Contact us
Location
GSK Investigational Site
Corsicana, Texas, United States, 75110
Status
Study Complete
Contact us
Location
GSK Investigational Site
Corvallis, Oregon, United States, 97330
Status
Study Complete
Contact us
Location
GSK Investigational Site
Coslada, Spain, 28822
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cottbus, Brandenburg, Germany, 03050
Status
Study Complete
Contact us
Location
GSK Investigational Site
Council Bluffs, Iowa, United States, 51503
Status
Study Complete
Contact us
Location
GSK Investigational Site
Crawley, United Kingdom, RH10 7DX
Status
Study Complete
Contact us
Location
GSK Investigational Site
Crowley, Louisiana, United States, 70526
Status
Study Complete
Contact us
Location
GSK Investigational Site
Crownhill, Plymouth, United Kingdom, PL5 3JB
Status
Study Complete
Contact us
Location
GSK Investigational Site
Curicó, Región Del Maule, Chile, 3341643
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cvikov, Czech Republic, 471 54
Status
Study Complete
Contact us
Location
GSK Investigational Site
Cáceres, Spain, 10003
Status
Study Complete
Contact us
Location
GSK Investigational Site
DEN BOSCH, Netherlands, 5223 GZ
Status
Study Complete
Contact us
Location
GSK Investigational Site
DORDRECHT, Netherlands, 3318 AT
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dachau, Bayern, Germany, 85221
Status
Study Complete
Contact us
Location
GSK Investigational Site
Danbury, Connecticut, United States, 06810
Status
Study Complete
Contact us
Location
GSK Investigational Site
Daw Park, South Australia, Australia, 5041
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dayton, Ohio, United States, 45459
Status
Study Complete
Contact us
Location
GSK Investigational Site
Daytona Beach, Florida, United States, 32117
Status
Study Complete
Contact us
Location
GSK Investigational Site
Decatur, Georgia, United States, 30033
Status
Study Complete
Contact us
Location
GSK Investigational Site
Deggendorf, Germany, 94469
Status
Study Complete
Contact us
Location
GSK Investigational Site
Deland, Florida, United States, 32720
Status
Study Complete
Contact us
Location
GSK Investigational Site
Delitzsch, Sachsen, Germany, 04509
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dillingen, Bayern, Germany, 89407
Status
Study Complete
Contact us
Location
GSK Investigational Site
Donaustauf, Bayern, Germany, 93093
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44263
Status
Study Complete
Contact us
Location
GSK Investigational Site
Downington, Pennsylvania, United States, 19335
Status
Study Complete
Contact us
Location
GSK Investigational Site
Doylestown, Pennsylvania, United States, 18901
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dueren, Nordrhein-Westfalen, Germany, 52349
Status
Study Complete
Contact us
Location
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47057
Status
Study Complete
Contact us
Location
GSK Investigational Site
Duluth, Georgia, United States, 30096
Status
Study Complete
Contact us
Location
GSK Investigational Site
Duluth, Minnesota, United States, 55805
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dundee, Scotland, United Kingdom, DD1 9SY
Status
Study Complete
Contact us
Location
GSK Investigational Site
Dunedin, New Zealand, 9012
Status
Study Complete
Contact us
Location
GSK Investigational Site
Durban, South Africa, 4001
Status
Study Complete
Contact us
Location
GSK Investigational Site
Durban, South Africa, 4091
Status
Study Complete
Contact us
Location
GSK Investigational Site
Durham, North Carolina, United States, 27710
Status
Study Complete
Contact us
Location
GSK Investigational Site
EINDHOVEN, Netherlands, 5623 EJ
Status
Study Complete
Contact us
Location
GSK Investigational Site
ENSCHEDE, Netherlands, 7513 ER
Status
Study Complete
Contact us
Location
GSK Investigational Site
Easley, South Carolina, United States, 29640
Status
Study Complete
Contact us
Location
GSK Investigational Site
East Providence, Rhode Island, United States, 02914
Status
Study Complete
Contact us
Location
GSK Investigational Site
Edgewater, Florida, United States, 32132
Status
Study Complete
Contact us
Location
GSK Investigational Site
Edina, Minnesota, United States, 55435
Status
Study Complete
Contact us
Location
GSK Investigational Site
Edinburg, Texas, United States, 78539
Status
Study Complete
Contact us
Location
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 2G3
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ehime, Japan, 791-0281
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ekaterinburg, Russia, 620109
Status
Study Complete
Contact us
Location
GSK Investigational Site
Elizabeth City, North Carolina, United States, 27909
Status
Study Complete
Contact us
Location
GSK Investigational Site
Elk Grove Village, Illinois, United States, 60007
Status
Study Complete
Contact us
Location
GSK Investigational Site
Encinitas, California, United States, 92024
Status
Study Complete
Contact us
Location
GSK Investigational Site
Erie, Pennsylvania, United States, 16508
Status
Study Complete
Contact us
Location
GSK Investigational Site
Erpent, Belgium, 5101
Status
Study Complete
Contact us
Location
GSK Investigational Site
Escondido, California, United States, 92025
Status
Study Complete
Contact us
Location
GSK Investigational Site
Espoo, Finland, 02740
Status
Study Complete
Contact us
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45277
Status
Study Complete
Contact us
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45355
Status
Study Complete
Contact us
Location
GSK Investigational Site
Evansville, Indiana, United States, 47714
Status
Study Complete
Contact us
Location
GSK Investigational Site
Everett, Washington, United States, 98208
Status
Study Complete
Contact us
Location
GSK Investigational Site
Exeter, Devon, United Kingdom, EX2 5DW
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fall River, Massachusetts, United States, 02720
Status
Study Complete
Contact us
Location
GSK Investigational Site
Feldbach, Austria, 8330
Status
Study Complete
Contact us
Location
GSK Investigational Site
Feldkirch, Austria, 6800
Status
Study Complete
Contact us
Location
GSK Investigational Site
Flagstaff, Arizona, United States, 86001
Status
Study Complete
Contact us
Location
GSK Investigational Site
Florence, Alabama, United States, 35630
Status
Study Complete
Contact us
Location
GSK Investigational Site
Florianopolis, Santa Catarina, Brazil, 88040-970
Status
Study Complete
Contact us
Location
GSK Investigational Site
Florida, Buenos Aires, Argentina, 1602
Status
Study Complete
Contact us
Location
GSK Investigational Site
Footscray, Victoria, Australia, 3011
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fort Collins, Colorado, United States, 80538
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fort Mill, South Carolina, United States, 29707
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fort Mitchell, Kentucky, United States, 41017
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fort Myers, Florida, United States, 33908
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fort Worth, Texas, United States, 76104
Status
Study Complete
Contact us
Location
GSK Investigational Site
Frankenberg, Hessen, Germany, 35066
Status
Study Complete
Contact us
Location
GSK Investigational Site
Frankfurt, Hessen, Germany, 60389
Status
Study Complete
Contact us
Location
GSK Investigational Site
Frankfurt, Hessen, Germany, 60596
Status
Study Complete
Contact us
Location
GSK Investigational Site
Franklin, Indiana, United States, 46131
Status
Study Complete
Contact us
Location
GSK Investigational Site
Frankston, Victoria, Australia, 3199
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fredrikstad, Norway, 1606
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fremont, Nebraska, United States, 68025
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fridley, Minnesota, United States, 55432
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fukuoka, Japan, 802-0052
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fukuoka, Japan, 802-0083
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fukuoka, Japan, 811-1394
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fukuoka, Japan, 816-0813
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fukuoka, Japan, 820-8505
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fukuoka, Japan, 832-0059
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fulda, Hessen, Germany, 36039
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fuldatal, Hessen, Germany, 34233
Status
Study Complete
Contact us
Location
GSK Investigational Site
Fuzhou, China, 350025
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gaffney, South Carolina, United States, 29340
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gainesville, Florida, United States, 32608
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gainesville, Georgia, United States, 30501
Status
Study Complete
Contact us
Location
GSK Investigational Site
Garmisch-Partenirchen, Bayern, Germany, 82467
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gastonia, North Carolina, United States, 28054
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gatesville, South Africa, 7764
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gatineau, Québec, Canada, J8Y 6S8
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gauting, Bayern, Germany, 82131
Status
Study Complete
Contact us
Location
GSK Investigational Site
Geelong, Victoria, Australia, 3220
Status
Study Complete
Contact us
Location
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany, 21502
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen, Germany, 45879
Status
Study Complete
Contact us
Location
GSK Investigational Site
Genk, Belgium, 3600
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gera, Thueringen, Germany, 07548
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gerona, Spain, 17005
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gifu, Japan, 500-8717
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gifu, Japan, 506-8550
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gifu, Japan, 509-6134
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gillespie, Illinois, United States, 62033
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gilly, Belgium, 6060
Status
Study Complete
Contact us
Location
GSK Investigational Site
Girona, Spain, 17007
Status
Study Complete
Contact us
Location
GSK Investigational Site
Glendale, Arizona, United States, 85306
Status
Study Complete
Contact us
Location
GSK Investigational Site
Golden, Colorado, United States, 80401
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gonzales, Texas, United States, 78629
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gosford, New South Wales, Australia, 2250
Status
Study Complete
Contact us
Location
GSK Investigational Site
Grand Island, Nebraska, United States, 68803
Status
Study Complete
Contact us
Location
GSK Investigational Site
Greenfield, Indiana, United States, 46140
Status
Study Complete
Contact us
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27403
Status
Study Complete
Contact us
Location
GSK Investigational Site
Greenville, South Carolina, United States, 29615
Status
Study Complete
Contact us
Location
GSK Investigational Site
Grenoble cedex 9, France, 38043
Status
Study Complete
Contact us
Location
GSK Investigational Site
Grieskirchen, Austria, A-4710
Status
Study Complete
Contact us
Location
GSK Investigational Site
Groningen, Netherlands, 9728 NT
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guangzhou, China, 510080
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guangzhou, Guangdong, China, 510080
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guangzhou, Guangdong, China, 510120
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guangzhou, Guangdong, China, 510150
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guangzhou, Guangdong, China, 510180
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guangzhou, Guangdong, China, 510630
Status
Study Complete
Contact us
Location
GSK Investigational Site
Guaynabo, Puerto Rico, Puerto Rico, 00968
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gummersbach, Nordrhein-Westfalen, Germany, 51643
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gunma, Japan, 372-0831
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gunma, Japan, 373-0807
Status
Study Complete
Contact us
Location
GSK Investigational Site
Gyeonggi-do, South Korea, 410-719
Status
Study Complete
Contact us
Location
GSK Investigational Site
GÖTEBORG, Sweden, SE-413 45
Status
Study Complete
Contact us
Location
GSK Investigational Site
GÖTEBORG, Sweden, SE-413 90
Status
Study Complete
Contact us
Location
GSK Investigational Site
HARDERWIJK, Netherlands, 3844 DG
Status
Study Complete
Contact us
Location
GSK Investigational Site
HELMOND, Netherlands, 5707 HA
Status
Study Complete
Contact us
Location
GSK Investigational Site
HOOFDDORP, Netherlands, 2134 TM
Status
Study Complete
Contact us
Location
GSK Investigational Site
HOORN, Netherlands, 1624 NP
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ha Noi, Vietnam, 10000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hagen, Nordrhein-Westfalen, Germany, 58089
Status
Study Complete
Contact us
Location
GSK Investigational Site
Haifa, Israel, 34362
Status
Study Complete
Contact us
Location
GSK Investigational Site
Haikou, Hainan, China, 570311
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hakadal, Norway, 1487
Status
Study Complete
Contact us
Location
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06108
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22291
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22299
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22763
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hamilton, Victoria, Australia, 3300
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hamilton, Ontario, Canada, L8L 5G8
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 3Z5
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hampton, Virginia, United States, 23666
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hangzhou, Zhejiang, China
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30167
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30173
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hartford, Connecticut, United States, 06105
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hasselt, Belgium, 3500
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hellerup, Denmark, 2900
Status
Study Complete
Contact us
Location
GSK Investigational Site
Helsinki, Finland, 00290
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hendersonville, North Carolina, United States, 28739
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hendersonville, Tennessee, United States, 37075
Status
Study Complete
Contact us
Location
GSK Investigational Site
High Heaton, Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE7 7DN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hines, Illinois, United States, 60124
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hiroshima, Japan, 722-8503
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hiroshima, Japan, 734-8530
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hiroshima, Japan, 735-8585
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ho Chi Minh, Vietnam, 70000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 001-0901
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 053-8506
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 060-0033
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 062-8618
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 063-0005
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 064-0801
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 064-0915
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 070-8644
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 071-8132
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hokkaido, Japan, 080-0805
Status
Study Complete
Contact us
Location
GSK Investigational Site
Holesov, Czech Republic, 769 01
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hollywood, Florida, United States, 33024
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hollywood, Maryland, United States, 20636
Status
Study Complete
Contact us
Location
GSK Investigational Site
Holon, Israel, 58100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Houston, Texas, United States, 77030
Status
Study Complete
Contact us
Location
GSK Investigational Site
Houston, Texas, United States, 77034
Status
Study Complete
Contact us
Location
GSK Investigational Site
Houston, Texas, United States, 77043
Status
Study Complete
Contact us
Location
GSK Investigational Site
Huntersville, North Carolina, United States, 28078
Status
Study Complete
Contact us
Location
GSK Investigational Site
Huntington Beach, California, United States, 92647
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hvidovre, Denmark, 2650
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 650-0047
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 651-0072
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 653-0013
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 664-8540
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 670-0849
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 672-8064
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 674-0063
Status
Study Complete
Contact us
Location
GSK Investigational Site
Hyogo, Japan, 675-8611
Status
Study Complete
Contact us
Location
GSK Investigational Site
HÖLLVIKEN, Sweden, SE-236 32
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ibaraki, Japan, 302-0022
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ibaraki, Japan, 310-0015
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ibaraki, Japan, 311-3193
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ibaraki, Japan, 317-0077
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ibaraki, Japan, 319-1113
Status
Study Complete
Contact us
Location
GSK Investigational Site
Iloilo, Philippines, 5000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Incheon, South Korea, 403-720
Status
Study Complete
Contact us
Location
GSK Investigational Site
Iowa City, Iowa, United States, 52242
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ishikawa, Japan, 920-8530
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ishikawa, Japan, 920-8610
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ishikawa, Japan, 921-8105
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ishikawa, Japan, 923-8560
Status
Study Complete
Contact us
Location
GSK Investigational Site
Istanbul, Turkey, 34020
Status
Study Complete
Contact us
Location
GSK Investigational Site
Istanbul, Turkey, 34844
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ivanovo, Russia, 153005
Status
Study Complete
Contact us
Location
GSK Investigational Site
Iwate, Japan, 020-0055
Status
Study Complete
Contact us
Location
GSK Investigational Site
Izmir, Turkey, 35100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jackson, Mississippi, United States, 39202
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32205
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32207
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32209
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32216
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jaro, Iloilo City, Philippines, 5000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jaromer, Czech Republic, 551 01
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jasper, Alabama, United States, 35501
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jeonju-si, South Korea, 561-712
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jerusalem, Israel, 91031
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jinan, Shandong, China, 250012
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jinan, Shandong, China, 250013
Status
Study Complete
Contact us
Location
GSK Investigational Site
Johannesburg, South Africa, 2113
Status
Study Complete
Contact us
Location
GSK Investigational Site
Johnson City, Tennessee, United States, 37601
Status
Study Complete
Contact us
Location
GSK Investigational Site
Johnstown, Pennsylvania, United States, 15905
Status
Study Complete
Contact us
Location
GSK Investigational Site
Jyvaskyla, Finland, 40100
Status
Study Complete
Contact us
Location
GSK Investigational Site
KLOOSTERHAAR, Netherlands, 7694 AC
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kagawa, Japan, 760-0018
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kagawa, Japan, 760-8538
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kagawa, Japan, 761-8073
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kagawa, Japan, 762-8550
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kanagawa, Japan, 210-0852
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kanagawa, Japan, 232-0024
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kanagawa, Japan, 232-0066
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kanagawa, Japan, 239-0821
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kanagawa, Japan, 252-5188
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kanagawa, Japan, 254-8502
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kangwon-do, South Korea, 220-701
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64128
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kassel, Hessen, Germany, 34121
Status
Study Complete
Contact us
Location
GSK Investigational Site
Katy, Texas, United States, 77450
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kazan, Russia, 420012
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kazan, Russia, 420015
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kerrville, Texas, United States, 78028
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kfar-Saba, Israel, 44281
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kharkiv, Ukraine, 61002
Status
Study Complete
Contact us
Location
GSK Investigational Site
Khon Kaen, Thailand, 40002
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kiev, Ukraine, 03680
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kingwood, Texas, United States, 77339
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kleve, Nordrhein-Westfalen, Germany, 47533
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kløfta, Norway, 2040
Status
Study Complete
Contact us
Location
GSK Investigational Site
Koblenz, Rheinland-Pfalz, Germany, 56068
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kochi, Japan, 780-8077
Status
Study Complete
Contact us
Location
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 51065
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kolding, Denmark, DK-6000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Korsten, South Africa, 6014
Status
Study Complete
Contact us
Location
GSK Investigational Site
Krasnodar, Russia, 350012
Status
Study Complete
Contact us
Location
GSK Investigational Site
Krasnoyarsk, Russia, 660022
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kumamoto, Japan, 861-1196
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kwun Tong, Hong Kong
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kyiv, Ukraine, 02232
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kyoto, Japan, 601-1495
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kyoto, Japan, 607-8062
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kyoto, Japan, 615-8087
Status
Study Complete
Contact us
Location
GSK Investigational Site
L'Hospitalet de Llobregat, Spain, 08907
Status
Study Complete
Contact us
Location
GSK Investigational Site
LEEUWARDEN, Netherlands, 8934 AD
Status
Study Complete
Contact us
Location
GSK Investigational Site
LINKÖPING, Sweden, SE-587 58
Status
Study Complete
Contact us
Location
GSK Investigational Site
LULEÅ, Sweden, SE-971 89
Status
Study Complete
Contact us
Location
GSK Investigational Site
La Coruña, Spain, 15006
Status
Study Complete
Contact us
Location
GSK Investigational Site
La Coruña, Spain, 15011
Status
Study Complete
Contact us
Location
GSK Investigational Site
La Plata, Buenos Aires, Argentina, 1900
Status
Study Complete
Contact us
Location
GSK Investigational Site
La Roca del Valles (Barcelona), Spain, 08430
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lafayette, Louisiana, United States, 70508
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lai Chi Kok, Hong Kong
Status
Study Complete
Contact us
Location
GSK Investigational Site
Landsberg, Bayern, Germany, 86899
Status
Study Complete
Contact us
Location
GSK Investigational Site
Laredo, Cantabria, Spain, 39770
Status
Study Complete
Contact us
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Study Complete
Contact us
Location
GSK Investigational Site
Le Mans, France, 72000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Leesburg, Florida, United States, 34748
Status
Study Complete
Contact us
Location
GSK Investigational Site
Leipzg, Sachsen, Germany, 04109
Status
Study Complete
Contact us
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04157
Status
Study Complete
Contact us
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04275
Status
Study Complete
Contact us
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04357
Status
Study Complete
Contact us
Location
GSK Investigational Site
Leonberg, Baden-Wuerttemberg, Germany, 71229
Status
Study Complete
Contact us
Location
GSK Investigational Site
Levanger, Norway, 7600
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lewisville, Texas, United States, 75067
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lexington, North Carolina, United States, 27292
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Peru, L 33
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Peru, L41
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Peru, Lima 32
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Peru, Lima 41
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Lima, Peru, 01
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Lima, Peru, Lima 1
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Lima, Peru, Lima 14
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Lima, Peru, Lima 18
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lima, Lima, Peru, Lima 27
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lincoln, Nebraska, United States, 68506
Status
Study Complete
Contact us
Location
GSK Investigational Site
Liverpool, Australia, 2107
Status
Study Complete
Contact us
Location
GSK Investigational Site
Liège, Belgium, 4000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lleida, Spain, 25198
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lohja, Finland, 08200
Status
Study Complete
Contact us
Location
GSK Investigational Site
Long Beach, California, United States, 90808
Status
Study Complete
Contact us
Location
GSK Investigational Site
Long Beach, California, United States, 90822
Status
Study Complete
Contact us
Location
GSK Investigational Site
Longview, Texas, United States, 75605
Status
Study Complete
Contact us
Location
GSK Investigational Site
Louisville, Kentucky, United States, 40218
Status
Study Complete
Contact us
Location
GSK Investigational Site
Loxahatchee, Florida, United States, 33470
Status
Study Complete
Contact us
Location
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23558
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lynchburg, Virginia, United States, 24501
Status
Study Complete
Contact us
Location
GSK Investigational Site
Lyon cedex 04, France, 69317
Status
Study Complete
Contact us
Location
GSK Investigational Site
Madrid, Spain, 28006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Madrid, Spain, 28040
Status
Study Complete
Contact us
Location
GSK Investigational Site
Maitland, Florida, United States, 32751
Status
Study Complete
Contact us
Location
GSK Investigational Site
Malmedy, Belgium, 4960
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68161
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68167
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, 7600
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Marbella - Málaga, Andalucia, Spain, 29603
Status
Study Complete
Contact us
Location
GSK Investigational Site
Marburg, Hessen, Germany, 35037
Status
Study Complete
Contact us
Location
GSK Investigational Site
Marion, Ohio, United States, 43302
Status
Study Complete
Contact us
Location
GSK Investigational Site
Maroubra, New South Wales, Australia, 2035
Status
Study Complete
Contact us
Location
GSK Investigational Site
Marseille cedex 03, France, 13331
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mataró, Spain, 08303
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mayaguez, Puerto Rico, Puerto Rico, 00680
Status
Study Complete
Contact us
Location
GSK Investigational Site
Medford, Oregon, United States, 97504
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mendoza, Mendoza, Argentina, 5500
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mendoza, Mendoza, Argentina, M5500CCG
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mersin, Turkey, 33343
Status
Study Complete
Contact us
Location
GSK Investigational Site
Miami, Florida, United States, 33015
Status
Study Complete
Contact us
Location
GSK Investigational Site
Middelburg, Mpumalanga, South Africa, 1055
Status
Study Complete
Contact us
Location
GSK Investigational Site
Middleburg Heights, Ohio, United States, 44130
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mie, Japan, 510-8567
Status
Study Complete
Contact us
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55402
Status
Study Complete
Contact us
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55407
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mirabel, Québec, Canada, J7J 2K8
Status
Study Complete
Contact us
Location
GSK Investigational Site
Missoula, Montana, United States, 59808
Status
Study Complete
Contact us
Location
GSK Investigational Site
Miyagi, Japan, 984-8560
Status
Study Complete
Contact us
Location
GSK Investigational Site
Miyagi, Japan, 986-8522
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mobile, Alabama, United States, 36608
Status
Study Complete
Contact us
Location
GSK Investigational Site
Moncton, New Brunswick, Canada, E1G 2K5
Status
Study Complete
Contact us
Location
GSK Investigational Site
Montauban cedex, France, 82017
Status
Study Complete
Contact us
Location
GSK Investigational Site
Monte Grande, Argentina, 1842
Status
Study Complete
Contact us
Location
GSK Investigational Site
Montigny-Le-Tilleul, Belgium, 6110
Status
Study Complete
Contact us
Location
GSK Investigational Site
Montpellier cedex 5, France, 34295
Status
Study Complete
Contact us
Location
GSK Investigational Site
Montréal, Québec, Canada, H1M 1B1
Status
Study Complete
Contact us
Location
GSK Investigational Site
Moorestown, New Jersey, United States, 08057
Status
Study Complete
Contact us
Location
GSK Investigational Site
Moscow, Russia, 119002
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mowbray, South Africa, 7700
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mt. Pleasant, South Carolina, United States, 29464
Status
Study Complete
Contact us
Location
GSK Investigational Site
Muang, Thailand, 11000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Muenchen, Bayern, Germany, 80339
Status
Study Complete
Contact us
Location
GSK Investigational Site
Muenchen, Bayern, Germany, 80539
Status
Study Complete
Contact us
Location
GSK Investigational Site
Muncie, Indiana, United States, 47303
Status
Study Complete
Contact us
Location
GSK Investigational Site
Murdoch, Western Australia, Australia, 6964
Status
Study Complete
Contact us
Location
GSK Investigational Site
Muscle Shoals, Alabama, United States, 35662
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mykolayiv, Ukraine, 54003
Status
Study Complete
Contact us
Location
GSK Investigational Site
Málaga, Spain, 29010
Status
Study Complete
Contact us
Location
GSK Investigational Site
Mérida (Badajoz), Spain, 06800
Status
Study Complete
Contact us
Location
GSK Investigational Site
NIEUWEGEIN, Netherlands, 3435 CM
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nagano, Japan, 392-8510
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nakhon Ratchasima, Thailand, 30000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nan, Thailand, 55000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nanchang, China, 330006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nanchang, Jiangxi, China, 330006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nanjing, Jiangsu, China, 210006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nanjing, Jiangsu, China, 210008
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nanjing, Jiangsu, China, 210029
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nanning, Guangxi, China, 530021
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nedlands, Western Australia, Australia, 6009
Status
Study Complete
Contact us
Location
GSK Investigational Site
Neptune, New Jersey, United States, 07753
Status
Study Complete
Contact us
Location
GSK Investigational Site
Neu isenburg, Hessen, Germany, 63263
Status
Study Complete
Contact us
Location
GSK Investigational Site
Neu-Ulm, Bayern, Germany, 89231
Status
Study Complete
Contact us
Location
GSK Investigational Site
Neuss, Nordrhein-Westfalen, Germany, 41462
Status
Study Complete
Contact us
Location
GSK Investigational Site
Neuwied, Rheinland-Pfalz, Germany, 56564
Status
Study Complete
Contact us
Location
GSK Investigational Site
New Haven, Connecticut, United States, 06520
Status
Study Complete
Contact us
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70112
Status
Study Complete
Contact us
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70115
Status
Study Complete
Contact us
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70119
Status
Study Complete
Contact us
Location
GSK Investigational Site
New Port Richey, Florida, United States, 34652
Status
Study Complete
Contact us
Location
GSK Investigational Site
New York, New York, United States, 10009
Status
Study Complete
Contact us
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Study Complete
Contact us
Location
GSK Investigational Site
New York, New York, United States, 10029
Status
Study Complete
Contact us
Location
GSK Investigational Site
Newport Beach, California, United States, 92663
Status
Study Complete
Contact us
Location
GSK Investigational Site
Newtown, Wellington, New Zealand, 6021
Status
Study Complete
Contact us
Location
GSK Investigational Site
Niigata, Japan, 940-0856
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nimes, France, 30900
Status
Study Complete
Contact us
Location
GSK Investigational Site
North Dartmouth, Massachusetts, United States, 02747
Status
Study Complete
Contact us
Location
GSK Investigational Site
Northwood, Middlesex, United Kingdom, HA6 2RN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Novgorod, Russia, 173008
Status
Study Complete
Contact us
Location
GSK Investigational Site
Novosibirsk, Russia, 630087
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nuernberg, Bayern, Germany, 90402
Status
Study Complete
Contact us
Location
GSK Investigational Site
Nueve de Julio, Buenos Aires, Argentina, B6500BWQ
Status
Study Complete
Contact us
Location
GSK Investigational Site
O'Fallon, Illinois, United States, 62269
Status
Study Complete
Contact us
Location
GSK Investigational Site
Odense C, Denmark, 5000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Odesa, Ukraine, 65025
Status
Study Complete
Contact us
Location
GSK Investigational Site
Oita, Japan, 870-0921
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okayama, Japan, 701-0304
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okayama, Japan, 702-8055
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okayama, Japan, 711-0921
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okinawa, Japan, 901-2121
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okinawa, Japan, 901-2132
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okinawa, Japan, 901-2393
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okinawa, Japan, 904-2143
Status
Study Complete
Contact us
Location
GSK Investigational Site
Okinawa, Japan, 904-2293
Status
Study Complete
Contact us
Location
GSK Investigational Site
Olathe, Kansas, United States, 66061
Status
Study Complete
Contact us
Location
GSK Investigational Site
Olomouc, Czech Republic, 772 00
Status
Study Complete
Contact us
Location
GSK Investigational Site
Omaha, Nebraska, United States, 68131
Status
Study Complete
Contact us
Location
GSK Investigational Site
Omaha, Nebraska, United States, 68134
Status
Study Complete
Contact us
Location
GSK Investigational Site
Oostende, Belgium, 8400
Status
Study Complete
Contact us
Location
GSK Investigational Site
Orlando, Florida, United States, 32825
Status
Study Complete
Contact us
Location
GSK Investigational Site
Orléans cedex 2, France, 45067
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 530-0001
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 533-0024
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 564-0013
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 576-0016
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 576-0041
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 591-8037
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 591-8555
Status
Study Complete
Contact us
Location
GSK Investigational Site
Osaka, Japan, 596-8501
Status
Study Complete
Contact us
Location
GSK Investigational Site
Oslo, Norway, 0953
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ostrava - Poruba, Czech Republic, 70868
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ostrowiec Swietokrzyski, Poland, 27-400
Status
Study Complete
Contact us
Location
GSK Investigational Site
Oviedo, Spain, 33006
Status
Study Complete
Contact us
Location
GSK Investigational Site
Oviedo, Florida, United States, 32765
Status
Study Complete
Contact us
Location
GSK Investigational Site
Paarl, South Africa, 7646
Status
Study Complete
Contact us
Location
GSK Investigational Site
Paducah, Kentucky, United States, 42003
Status
Study Complete
Contact us
Location
GSK Investigational Site
Palma de Mallorca, Spain, 07120
Status
Study Complete
Contact us
Location
GSK Investigational Site
Palo Alto, California, United States, 94304
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pamplona, Spain, 31008
Status
Study Complete
Contact us
Location
GSK Investigational Site
Panorama, South Africa, 7500
Status
Study Complete
Contact us
Location
GSK Investigational Site
Paraná, Buenos Aires, Argentina, E3100BHK
Status
Study Complete
Contact us
Location
GSK Investigational Site
Paris, France, 75014
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pasig, Philippines, 1605
Status
Study Complete
Contact us
Location
GSK Investigational Site
Peine, Niedersachsen, Germany, 31224
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pembroke Pines, Florida, United States, 33027
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pensacola, Florida, United States, 32503
Status
Study Complete
Contact us
Location
GSK Investigational Site
Peoria, Arizona, United States, 85381
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pessac cedex, France, 33604
Status
Study Complete
Contact us
Location
GSK Investigational Site
Petah Tikva, Israel, 49100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Petrer/Alicante, Spain, 03610
Status
Study Complete
Contact us
Location
GSK Investigational Site
Petrozavodsk, Russia, 185019
Status
Study Complete
Contact us
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Status
Study Complete
Contact us
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140
Status
Study Complete
Contact us
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19142
Status
Study Complete
Contact us
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85018
Status
Study Complete
Contact us
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85032
Status
Study Complete
Contact us
Location
GSK Investigational Site
Phoenixville, Pennsylvania, United States, 19460
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15241
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15243
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pittsfield, Massachusetts, United States, 01201
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ploiesti, Romania, 100184
Status
Study Complete
Contact us
Location
GSK Investigational Site
Plzen, Czech Republic, 301 00
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pokfulam, Hong Kong
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ponce, Puerto Rico, Puerto Rico, 00716
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ponferrada (León), Spain, 24411
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ponte Verda, Florida, United States, 32081
Status
Study Complete
Contact us
Location
GSK Investigational Site
Port Charlotte, Florida, United States, 33952
Status
Study Complete
Contact us
Location
GSK Investigational Site
Port Charlotte, Florida, United States, 33980
Status
Study Complete
Contact us
Location
GSK Investigational Site
Port Orange, Florida, United States, 32127
Status
Study Complete
Contact us
Location
GSK Investigational Site
Portland, Oregon, United States, 97220
Status
Study Complete
Contact us
Location
GSK Investigational Site
Portland, Oregon, United States, 97225
Status
Study Complete
Contact us
Location
GSK Investigational Site
Portland, Oregon, United States, 97239
Status
Study Complete
Contact us
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-074
Status
Study Complete
Contact us
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90480-000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Potsdam, Brandenburg, Germany, 14467
Status
Study Complete
Contact us
Location
GSK Investigational Site
Potsdam, Brandenburg, Germany, 14469
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pozuelo de Alarcón/Madrid, Spain, 28223
Status
Study Complete
Contact us
Location
GSK Investigational Site
Praha 5, Czech Republic, 150 06
Status
Study Complete
Contact us
Location
GSK Investigational Site
Praha 8, Czech Republic, 182 00
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pretoria, Gauteng, South Africa, 0183
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pringy cedex, France, 74374
Status
Study Complete
Contact us
Location
GSK Investigational Site
Puente Alto - Santiago, Región Metro De Santiago, Chile, 8207257
Status
Study Complete
Contact us
Location
GSK Investigational Site
Pyatigorsk, Russia, 357538
Status
Study Complete
Contact us
Location
GSK Investigational Site
Qingdao, Shandong, China, 266071
Status
Study Complete
Contact us
Location
GSK Investigational Site
Quebec, Québec, Canada, G1V 4G5
Status
Study Complete
Contact us
Location
GSK Investigational Site
Quebec, Québec, Canada, G3K 2P8
Status
Study Complete
Contact us
Location
GSK Investigational Site
Quezon City, Philippines, 1100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Quincy, Illinois, United States, 62301
Status
Study Complete
Contact us
Location
GSK Investigational Site
ROTTERDAM, Netherlands, 3083 AN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ramat Gan, Israel, 52621
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ramnicu Valcea, Romania, 240564
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rapid City, South Dakota, United States, 57702
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rathenow, Brandenburg, Germany, 14712
Status
Study Complete
Contact us
Location
GSK Investigational Site
Recife, Pernambuco, Brazil, 50920-900
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rehovot, Israel, 76100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Reinfeld, Schleswig-Holstein, Germany, 23858
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rennes Cedex 9, France, 35033
Status
Study Complete
Contact us
Location
GSK Investigational Site
Reno, Nevada, United States, 89503
Status
Study Complete
Contact us
Location
GSK Investigational Site
Renton, Washington, United States, 98055
Status
Study Complete
Contact us
Location
GSK Investigational Site
Renton, Washington, United States, 98057
Status
Study Complete
Contact us
Location
GSK Investigational Site
Reseda, California, United States, 91335
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rheine, Nordrhein-Westfalen, Germany, 48431
Status
Study Complete
Contact us
Location
GSK Investigational Site
Richmond, Virginia, United States, 23225
Status
Study Complete
Contact us
Location
GSK Investigational Site
Richmond, Virginia, United States, 23229
Status
Study Complete
Contact us
Location
GSK Investigational Site
Richmond, Virginia, United States, 23249
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rincon, Georgia, United States, 31326
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rio de Janeiro, Brazil, 21941-913
Status
Study Complete
Contact us
Location
GSK Investigational Site
Riverside, California, United States, 92506
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rochester, Minnesota, United States, 55905
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rock Hill, South Carolina, United States, 29732
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rodgau, Hessen, Germany, 63110
Status
Study Complete
Contact us
Location
GSK Investigational Site
Roeselaere, Belgium, 8800
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rolling Hills Estates, California, United States, 90274
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rosario, Santa Fe, Argentina, 2000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2002OJN
Status
Study Complete
Contact us
Location
GSK Investigational Site
Rosenheim, Bayern, Germany, 83022
Status
Study Complete
Contact us
Location
GSK Investigational Site
Roskilde, Denmark, 4000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ruedersdorf, Brandenburg, Germany, 15562
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ruesselsheim, Hessen, Germany, 65428
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ryazan, Russia, 390005
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ryazan, Russia, 390039
Status
Study Complete
Contact us
Location
GSK Investigational Site
SNEEK, Netherlands, 8601 ZR
Status
Study Complete
Contact us
Location
GSK Investigational Site
SPIJKENISSE, Netherlands, 3207 NB
Status
Study Complete
Contact us
Location
GSK Investigational Site
STOCKHOLM, Sweden, SE-111 57
Status
Study Complete
Contact us
Location
GSK Investigational Site
Saalfeld, Thueringen, Germany, 07318
Status
Study Complete
Contact us
Location
GSK Investigational Site
Saarbruecken, Saarland, Germany, 66111
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sabadell (Barcelona), Spain, 08208
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sacramento, California, United States, 95821
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sagunto/Valencia, Spain, 46520
Status
Study Complete
Contact us
Location
GSK Investigational Site
Saint-Petersburg, Russia, 194354
Status
Study Complete
Contact us
Location
GSK Investigational Site
Saitama, Japan, 349-1105
Status
Study Complete
Contact us
Location
GSK Investigational Site
Salamanca, Spain, 37007
Status
Study Complete
Contact us
Location
GSK Investigational Site
Salta, Salta, Argentina, A4400ERH
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Antonio, Texas, United States, 78215
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Diego, California, United States, 92117
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico, 00921
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico, 00927
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Juan De Alicante, Spain, 3550
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Martin de Porres, Lima, Peru, Lima 31
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Miguel, Lima, Peru, Lima 32
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Miguel de Tucuman, Tucumán, Argentina, 4000
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Miguel de Tucumán, Argentina, 4000
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Rafael, Mendoza, Argentina, 5600
Status
Study Complete
Contact us
Location
GSK Investigational Site
San Sebastian de los Reyes, Spain, 28702
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santa Ana, California, United States, 92705
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santa Fe, Santa Fe, Argentina, 3000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santa Monica, California, United States, 90404
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santa Rosa, Argentina, 6300
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santander, Spain, 39008
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santiago, Chile, 7500698
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500692
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 8360160
Status
Study Complete
Contact us
Location
GSK Investigational Site
Santiago de Compostela, Spain, 15706
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sarasota, Florida, United States, 34239
Status
Study Complete
Contact us
Location
GSK Investigational Site
Saratov, Russia, 410053
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sarnia, Ontario, Canada, N7T 4X3
Status
Study Complete
Contact us
Location
GSK Investigational Site
Schleswig, Schleswig-Holstein, Germany, 24837
Status
Study Complete
Contact us
Location
GSK Investigational Site
Schmoelln, Thueringen, Germany, 04626
Status
Study Complete
Contact us
Location
GSK Investigational Site
Seneca, South Carolina, United States, 29678
Status
Study Complete
Contact us
Location
GSK Investigational Site
Seoul, South Korea, 110-744
Status
Study Complete
Contact us
Location
GSK Investigational Site
Seoul, South Korea, 130-872
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sevilla, Spain, 41013
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shanghai, China, 200025
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shanghai, China, 200433
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shatin, Hong Kong
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sheffield, Alabama, United States, 35660
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shelby, North Carolina, United States, 28150
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shelby, North Carolina, United States, 28152
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shenyang, Liaoning, China, 110004
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shenyang, Liaoning, China, 110015
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sherwood Park, Alberta, Canada, T8H 0N2
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shijiazhuang, Hebei, China, 050000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shizuoka, Japan, 420-8527
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shizuoka, Japan, 430-8525
Status
Study Complete
Contact us
Location
GSK Investigational Site
Shreveport, Louisiana, United States, 71103
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sidcup, Kent, United Kingdom, DA14 6LT
Status
Study Complete
Contact us
Location
GSK Investigational Site
Singapore, Singapore, 117599
Status
Study Complete
Contact us
Location
GSK Investigational Site
Singapore, Singapore, 169856
Status
Study Complete
Contact us
Location
GSK Investigational Site
Singapore, Singapore, 529889
Status
Study Complete
Contact us
Location
GSK Investigational Site
Singapore, Singapore, 609606
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sioux Falls, South Dakota, United States, 57108
Status
Study Complete
Contact us
Location
GSK Investigational Site
Solingen, Nordrhein-Westfalen, Germany, 42699
Status
Study Complete
Contact us
Location
GSK Investigational Site
Songkla, Thailand, 90110
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sopot, Poland, 81-741
Status
Study Complete
Contact us
Location
GSK Investigational Site
Southfield, Michigan, United States, 48034
Status
Study Complete
Contact us
Location
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
Status
Study Complete
Contact us
Location
GSK Investigational Site
Spokane Valley, Washington, United States, 99216
Status
Study Complete
Contact us
Location
GSK Investigational Site
St-Charles-Borromée, Québec, Canada, J6E 2B4
Status
Study Complete
Contact us
Location
GSK Investigational Site
St. Charles, Missouri, United States, 63301
Status
Study Complete
Contact us
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63141
Status
Study Complete
Contact us
Location
GSK Investigational Site
St. Paul, Minnesota, United States, 55130
Status
Study Complete
Contact us
Location
GSK Investigational Site
St. Petersburg, Russia, 194356
Status
Study Complete
Contact us
Location
GSK Investigational Site
St. Petersburg, Russia, 198216
Status
Study Complete
Contact us
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33704
Status
Study Complete
Contact us
Location
GSK Investigational Site
St.Louis, Missouri, United States, 63141
Status
Study Complete
Contact us
Location
GSK Investigational Site
Stamford, Connecticut, United States, 06902
Status
Study Complete
Contact us
Location
GSK Investigational Site
Stavanger, Norway, 4005
Status
Study Complete
Contact us
Location
GSK Investigational Site
Stavanger, Norway, 4011
Status
Study Complete
Contact us
Location
GSK Investigational Site
Stavropol, Russia, 355017
Status
Study Complete
Contact us
Location
GSK Investigational Site
Stockton-on-Tees, United Kingdom, TS19 8PE
Status
Study Complete
Contact us
Location
GSK Investigational Site
Strasbourg cedex, France, 67091
Status
Study Complete
Contact us
Location
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70378
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sudbury, Ontario, Canada, P3A 1Y8
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sudbury, Ontario, Canada, P3E 1H5
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sugar Land, Texas, United States, 77479
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sumy, Ukraine, 40022
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sunset, Louisiana, United States, 70584
Status
Study Complete
Contact us
Location
GSK Investigational Site
Suwon, South Korea, 442-723
Status
Study Complete
Contact us
Location
GSK Investigational Site
Syracuse, New York, United States, 13210
Status
Study Complete
Contact us
Location
GSK Investigational Site
Szczecin, Poland, 71-124
Status
Study Complete
Contact us
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 01323903
Status
Study Complete
Contact us
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 04266-010
Status
Study Complete
Contact us
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 05403-000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Sønderborg, Denmark, 6400
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tabor City, North Carolina, United States, 28463
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Contact us
Location
GSK Investigational Site
Taiyuan, Shanxi, China, 030001
Status
Study Complete
Contact us
Location
GSK Investigational Site
Talca, Región Del Maule, Chile, 3465584
Status
Study Complete
Contact us
Location
GSK Investigational Site
Talcahuano, Chile, 4270918
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tampa, Florida, United States, 33603
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tampere, Finland, 33520
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tarnów, Poland, 33-100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tarragona, Spain, 43002
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tauranga, New Zealand, 3110
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tauranga, New Zealand, 3112
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tel Aviv, Israel, 67891
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tel-Aviv, Israel, 64239
Status
Study Complete
Contact us
Location
GSK Investigational Site
Teplice, Czech Republic, 415 10
Status
Study Complete
Contact us
Location
GSK Investigational Site
Teuchern, Sachsen-Anhalt, Germany, 06682
Status
Study Complete
Contact us
Location
GSK Investigational Site
Thalheim bei Wels, Austria, 4600
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tianjin, China, 300052
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tipton, Pennsylvania, United States, 16684
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tochigi, Japan, 320-0065
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 103-0027
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 103-0028
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 104-8560
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 120-0033
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 134-0083
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 158-8531
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 194-0023
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 198-0042
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 204-8585
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toledo, Ohio, United States, 43606
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toledo, Ohio, United States, 43617
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tomball, Texas, United States, 77375
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tomsk, Russia, 634009
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tomsk, Russia, 634050
Status
Study Complete
Contact us
Location
GSK Investigational Site
Topeka, Kansas, United States, 66606
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toronto, Ontario, Canada, M3J 2C5
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toronto, Ontario, Canada, M4S 1Y2
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toronto, Ontario, Canada, M5T 3A9
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toronto, Ontario, Canada, M9W 4L6
Status
Study Complete
Contact us
Location
GSK Investigational Site
Torrance, California, United States, 90505
Status
Study Complete
Contact us
Location
GSK Investigational Site
Torrelavega, Cantabria, Spain, 39300
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toulon, France, 83000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toyama, Japan, 937-0042
Status
Study Complete
Contact us
Location
GSK Investigational Site
Toyama, Japan, 938-8502
Status
Study Complete
Contact us
Location
GSK Investigational Site
Trebic, Czech Republic, 674 01
Status
Study Complete
Contact us
Location
GSK Investigational Site
Trois Rivieres, Québec, Canada, G8T 7A1
Status
Study Complete
Contact us
Location
GSK Investigational Site
Trondheim, Norway, 7027
Status
Study Complete
Contact us
Location
GSK Investigational Site
Trowbridge, United Kingdom, BA14 9AR
Status
Study Complete
Contact us
Location
GSK Investigational Site
Troy, Michigan, United States, 48085
Status
Study Complete
Contact us
Location
GSK Investigational Site
Truro, Nova Scotia, Canada, B2N 1L2
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tucson, Arizona, United States, 85723
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tucson, Arizona, United States, 85724-5023
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tucson, Arizona, United States, 85745
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tuen Mun, Hong Kong
Status
Study Complete
Contact us
Location
GSK Investigational Site
Turku, Finland, 20100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Turku, Finland, 20520
Status
Study Complete
Contact us
Location
GSK Investigational Site
Turnhout, Belgium, 2300
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tustin, California, United States, 92780
Status
Study Complete
Contact us
Location
GSK Investigational Site
Tygerberg, South Africa, 7505
Status
Study Complete
Contact us
Location
GSK Investigational Site
UPPSALA, Sweden, SE-752 37
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ulan-Ude, Russia, 670031
Status
Study Complete
Contact us
Location
GSK Investigational Site
Ulyanovsk, Russia, 432063
Status
Study Complete
Contact us
Location
GSK Investigational Site
Union, South Carolina, United States, 29379
Status
Study Complete
Contact us
Location
GSK Investigational Site
Upland, California, United States, 91786
Status
Study Complete
Contact us
Location
GSK Investigational Site
VELDHOVEN, Netherlands, 5504 DB
Status
Study Complete
Contact us
Location
GSK Investigational Site
Val de Grace, Pretoria, Gauteng, South Africa, 0184
Status
Study Complete
Contact us
Location
GSK Investigational Site
Valencia, Spain, 46015
Status
Study Complete
Contact us
Location
GSK Investigational Site
Valencia, Spain, 46017
Status
Study Complete
Contact us
Location
GSK Investigational Site
Valladolid, Spain, 47012
Status
Study Complete
Contact us
Location
GSK Investigational Site
Valparaiso, Valparaíso, Chile, 2341131
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vandoeuvre-les-Nancy, France, 54511
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vicente Lopez, Buenos Aires, Argentina, B1602DOH
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vienna, Austria, A-1030
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vinnytsia, Ukraine, 21000
Status
Study Complete
Contact us
Location
GSK Investigational Site
Virginia Beach, Virginia, United States, 23454
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vizcaya, Spain, 48902
Status
Study Complete
Contact us
Location
GSK Investigational Site
Viña del Mar, Chile, 2520594
Status
Study Complete
Contact us
Location
GSK Investigational Site
Viña del Mar, Valparaíso, Chile, 2520024
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vladimir, Russia, 600023
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vladivostok, Russia, 690002
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vladivostok, Russia, 690950
Status
Study Complete
Contact us
Location
GSK Investigational Site
Volgodonsk, Russia, 347381
Status
Study Complete
Contact us
Location
GSK Investigational Site
Voronezh, Russia, 394066
Status
Study Complete
Contact us
Location
GSK Investigational Site
Vsevolozhsk, Leningrad Region, Russia, 188640
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wakayama, Japan, 640-8558
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wallerfing, Bayern, Germany, 94574
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wardenburg, Niedersachsen, Germany, 26203
Status
Study Complete
Contact us
Location
GSK Investigational Site
Warendorf, Nordrhein-Westfalen, Germany, 48231
Status
Study Complete
Contact us
Location
GSK Investigational Site
Waterbury, Connecticut, United States, 06708
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wellington, New Zealand, 6021
Status
Study Complete
Contact us
Location
GSK Investigational Site
Westmead, New South Wales, Australia, 2145
Status
Study Complete
Contact us
Location
GSK Investigational Site
Whiteville, North Carolina, United States, 28472
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wichita, Kansas, United States, 67218
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wiesloch, Baden-Wuerttemberg, Germany, 69168
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wilmington, North Carolina, United States, 28401
Status
Study Complete
Contact us
Location
GSK Investigational Site
Windsor, Ontario, Canada, N8X 5A6
Status
Study Complete
Contact us
Location
GSK Investigational Site
Winfield, Illinois, United States, 60190
Status
Study Complete
Contact us
Location
GSK Investigational Site
Winnipeg, Manitoba, Canada, R2H 2A6
Status
Study Complete
Contact us
Location
GSK Investigational Site
Winnipeg, Manitoba, Canada, R2K 3S8
Status
Study Complete
Contact us
Location
GSK Investigational Site
Winston Salem, North Carolina, United States, 27103
Status
Study Complete
Contact us
Location
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wishaw, Lanarkshire, United Kingdom, ML2 0DP
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wissen, Rheinland-Pfalz, Germany, 57537
Status
Study Complete
Contact us
Location
GSK Investigational Site
Witten, Germany, 58452
Status
Study Complete
Contact us
Location
GSK Investigational Site
Witten, Nordrhein-Westfalen, Germany, 58452
Status
Study Complete
Contact us
Location
GSK Investigational Site
Woodbury, Minnesota, United States, 55125
Status
Study Complete
Contact us
Location
GSK Investigational Site
Woodstock, Georgia, United States, 30189
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wooster, Ohio, United States, 44691
Status
Study Complete
Contact us
Location
GSK Investigational Site
Worcester, Massachusetts, United States, 01608
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wuxi, China, 214023
Status
Study Complete
Contact us
Location
GSK Investigational Site
Wyomissing, Pennsylvania, United States, 19610
Status
Study Complete
Contact us
Location
GSK Investigational Site
Xian, Shanxi, China, 710032
Status
Study Complete
Contact us
Location
GSK Investigational Site
Yamagata, Japan, 990-8533
Status
Study Complete
Contact us
Location
GSK Investigational Site
Yamanashi, Japan, 400-0031
Status
Study Complete
Contact us
Location
GSK Investigational Site
Yamanashi, Japan, 400-8506
Status
Study Complete
Contact us
Location
GSK Investigational Site
Yaroslavl, Russia, 150003
Status
Study Complete
Contact us
Location
GSK Investigational Site
Yaroslavl, Russia, 150010
Status
Study Complete
Contact us
Location
GSK Investigational Site
Yinchuan, Ningxia, China, 750004
Status
Study Complete
Contact us
Location
GSK Investigational Site
ZUTPHEN, Netherlands, 7207 AE
Status
Study Complete
Contact us
Location
GSK Investigational Site
ZWOLLE, Netherlands, 8025 AB
Status
Study Complete
Contact us
Location
GSK Investigational Site
Zaragoza, Spain, 50009
Status
Study Complete
Contact us
Location
GSK Investigational Site
Zerbst, Sachsen-Anhalt, Germany, 39261
Status
Study Complete
Contact us
Location
GSK Investigational Site
Zgierz, Poland, 95-100
Status
Study Complete
Contact us
Location
GSK Investigational Site
Zhanjiang, Guangdong, China, 524001
Status
Study Complete
Contact us
Location
GSK Investigational Site
peralada( Girona), Spain, 17491
Status
Study Complete
Contact us
Location
GSK Investigational Site
ÖREBRO, Sweden, SE-703 62
Status
Study Complete
Contact us
Location
GSK Investigational Site
ÖSTERSUND, Sweden, SE-831 83
Status
Study Complete
Contact us

Study documents

Clinical study report
Available language(s): English
Download document(s)
Protocol
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2017-17-07
Actual study completion date
2017-17-07

Plain language summaries

Summary of results in plain language
Available language(s): Swedish, Czech, Danish, German, Finnish, French, Malay, Dutch, Polish, Portuguese (Latin America), Romanian, Russian, Turkish, Chinese (Simplified), Ukrainian, Korean, Spanish, Norwegian, Thai, Afrikaans, Hebrew, English (UK), Vietnam, Filipino-Tagalog, Japanese
Download document(s)

To view plain language summaries on trialsummaries.com click here.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website